Curium, a world leader in nuclear medicine, announced that today in Munich and Nurnberg, Germany the first commercial doses ...

Curium, a world leader in nuclear medicine, announced today that it has successfully enrolled and scanned patients in its ...

The proposed acquisition of Eczacıbaşı-Monrol will: Build on existing partnership in Lu-177 creating a leading manufacturer of the isotope Add 12 PET sites to Curium’s existing network in ...

If you look at a current version of the periodic table, it appears complete. Since 2010, the entire seventh period has been ...

This is the second part of a three-part series written by Carolyn Krause. Many of the elements were synthesized using an Oak ...

ST. LOUIS, April 23, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has successfully enrolled and scanned patients in its SOLAR clinical trials ...

About Curium Curium is a world leader in nuclear medicine. We develop, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe.

PARIS, April 09, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that today in the Netherlands the first commercial dose of PYLCLARI® has been sold. PYLCLARI® (INN ...

Try refreshing your browser, or tap here to see other videos from our team. Curium Plans to Significantly Expand Lutetium-177 Capacity and Pet Footprint With Agreement to Acquire Eczacibaşi-Monrol ...

Build on existing partnership in Lu-177 creating a leading manufacturer of the isotope Add 12 PET sites to Curium's existing network in geographies where Curium is not present today Add SPECT ...